MELA Sciences Inc  

(Public, NASDAQ:MELA)   Watch this stock  
Find more results for MELA
1.95
-0.01 (-0.51%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.88 - 2.15
52 week 1.65 - 10.40
Open 1.91
Vol / Avg. 120,337.00/41,247.00
Mkt cap 10.17M
P/E     -
Div/yield     -
EPS -4.23
Shares 5.21M
Beta -0.02
Inst. own 15%
Sep 18, 2014
MELA Sciences Inc at Craig-Hallum Alpha Select Conference
Sep 9, 2014
MELA Sciences Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2014
Q2 2014 MELA Sciences Inc Earnings Call - Webcast
Aug 13, 2014
Q2 2014 MELA Sciences Earnings Release
Aug 13, 2014
MELA Sciences Inc Key Opinion Leader Breakfast Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 278.49% -4841.05%
Operating margin -1904.36% -4502.61%
EBITD margin - -3840.30%
Return on average assets 16.85% -165.27%
Return on average equity 37.27% -233.02%
Employees 45 -
CDP Score - -

Address

Suite 1, 50 South Buckhout St.
IRVINGTON, NY 10533
United States - Map
+1-914-5913783 (Phone)
+1-914-5913785 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MELA Sciences, Inc. is a medical device company focused on the commercialization of its product, MelaFind, and the further design and development of MelaFind and its technology. MelaFind is a non-invasive, point-of-care (in the doctor's office) instrument to aid in the detection of melanoma. MelaFind, features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing classification algorithms, trained on the Company's database of melanomas and benign lesions, to provide information to assist in the management of the patient's disease, including information useful in the decision whether to biopsy the lesion.

Officers and directors

Jeffrey F. O'Donnell Sr. Chairman of the Board
Bio & Compensation  - Reuters
Rosemary A. Crane President, Chief Executive Officer, Treasurer, Secretary, Director
Age: 54
Bio & Compensation  - Reuters
Robert W. Cook Principal Financial Officer, Treasurer, Secretary
Age: 58
Bio & Compensation  - Reuters
Robert C. Coradini Director
Age: 54
Bio & Compensation  - Reuters
Tony Dimun Director
Age: 70
Bio & Compensation  - Reuters
David K. Stone Director
Age: 57
Bio & Compensation  - Reuters
Kathryn B. Swintek Director
Age: 61
Bio & Compensation  - Reuters
LuAnn Via Director
Age: 60
Bio & Compensation  - Reuters